Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/27291
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNolan, Brendan James-
dc.contributor.authorCheung, Ada S-
dc.date2021-06-02-
dc.date.accessioned2021-08-23T05:58:56Z-
dc.date.available2021-08-23T05:58:56Z-
dc.date.issued2021-06-02-
dc.identifier.citationTransgender Health 2021; 6(3): 125-131en
dc.identifier.issn2688-4887
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/27291-
dc.description.abstractTransgender, including gender diverse and nonbinary, individuals are treated with estradiol with or without antiandrogen to align their physical appearance with their gender identity, improve mental health and quality of life. Consensus guidelines give target ranges for serum estradiol concentration based on premenopausal female reference ranges. However, limited studies have evaluated the relationship between serum estradiol concentrations and clinical outcomes in transgender individuals undergoing feminizing hormone therapy. The available evidence has not found that higher serum estradiol concentrations, together with suppressed testosterone, enhance breast development, or produce more feminine changes to body composition. However, ensuring testosterone suppression appears to be an important factor to maximize these physical changes. Higher serum estradiol concentrations have been associated with higher areal bone mineral density. Although the resultant long-term clinical implications are yet to be determined, this could be a consideration for individuals with low bone mass. The precise serum estradiol concentration that results in adequate feminization without increasing the risk of complications (thromboembolic disease, cholelithiasis) remains unknown. Further prospective trials are required.en
dc.language.isoeng
dc.subjectbody compositionen
dc.subjectboneen
dc.subjectbreasten
dc.subjectestradiolen
dc.subjecttransgenderen
dc.titleRelationship Between Serum Estradiol Concentrations and Clinical Outcomes in Transgender Individuals Undergoing Feminizing Hormone Therapy: A Narrative Review.en
dc.typeJournal Articleen
dc.identifier.journaltitleTransgender Healthen
dc.identifier.affiliationEndocrinologyen
dc.identifier.affiliationMedicine (University of Melbourne)en
dc.identifier.doi10.1089/trgh.2020.0077en
dc.type.contentTexten
dc.identifier.pubmedid34414268
local.name.researcherCheung, Ada S
item.languageiso639-1en-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

30
checked on Nov 8, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.